[Current events in immunotherapy for upper aerodigestive tract cancer].

[1]  S. Oudard,et al.  Immunothérapie des cancers : rationnel et avancées récentes , 2016 .

[2]  S. Pai,et al.  The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. , 2016, Oral oncology.

[3]  R. Berger,et al.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Wherry,et al.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. , 2016, Immunity.

[5]  K. Harrington,et al.  Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 , 2016 .

[6]  Ping Wang,et al.  Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis , 2016, Targeted Oncology.

[7]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[8]  N. Hato,et al.  Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomas , 2016, Journal of surgical oncology.

[9]  V. Lee,et al.  Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma , 2016, PloS one.

[10]  O. Mariani,et al.  Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas , 2016, Oncotarget.

[11]  A. Psyrri,et al.  Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers , 2016, Current Treatment Options in Oncology.

[12]  J. Hipp,et al.  Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? , 2016, Drugs.

[13]  K. Harrington,et al.  Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. , 2016 .

[14]  J. Gilbert,et al.  Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. , 2016 .

[15]  H. Kreipe,et al.  Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[16]  B. Fox,et al.  OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer , 2016, Clinical & translational immunology.

[17]  E. Tartour,et al.  Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine , 2016, Clinical Cancer Research.

[18]  L. Bu,et al.  CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma , 2016, Oncoimmunology.

[19]  G. Freeman,et al.  Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. , 2016, Cancer research.

[20]  P. Das,et al.  CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma. , 2016, Stem cell research.

[21]  Ju-Seog Lee,et al.  PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma , 2016, Oncotarget.

[22]  H. Mai,et al.  Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma , 2016, Oncotarget.

[23]  Howard Y. Chang,et al.  CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1 , 2016, Clinical Cancer Research.

[24]  M. Einstein,et al.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases , 2016, Human vaccines & immunotherapeutics.

[25]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[26]  Yingdong Zhao,et al.  Novel technologies and emerging biomarkers for personalized cancer immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[27]  F. Hirsch,et al.  Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? , 2016, Archives of pathology & laboratory medicine.

[28]  T. Vaněček,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion , 2016, The American journal of surgical pathology.

[29]  J. Knezetic,et al.  Molecular profiling of head and neck squamous cell carcinoma , 2015, Head & neck.

[30]  M. Ahn,et al.  Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[31]  Chiun Hsu,et al.  315O_PRAntitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study , 2015 .

[32]  J. Phookan,et al.  Negative regulation of natural killer cell in tumor tissue and peripheral blood of oral squamous cell carcinoma. , 2015, Cytokine.

[33]  A. Kulkarni,et al.  PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma , 2015, Oncotarget.

[34]  E. Tartour,et al.  Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines , 2015, Clinical Cancer Research.

[35]  G. Freeman,et al.  Immunologic profiling of adenoid cystic carcinoma (acc) , 2015, Journal of Immunotherapy for Cancer.

[36]  T. Mcclanahan,et al.  18LBA PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer , 2015 .

[37]  S. Grupp,et al.  Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street , 2015, The Journal of Immunology.

[38]  K. Curran,et al.  Chimeric antigen receptor T cells for cancer immunotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[40]  M. Azuma,et al.  Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.

[41]  W. Liang,et al.  Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma , 2015, Medical Oncology.

[42]  V. Sondak,et al.  Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 , 2015, Cancer.

[43]  J. Bouček,et al.  Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma , 2015, Oncoimmunology.

[44]  E. King,et al.  Staging and treatment of oropharyngeal cancer in the human papillomavirus era , 2014, Head & neck.

[45]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[46]  W. Liang,et al.  EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy , 2014, Oncotarget.

[47]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[48]  E. Tartour,et al.  Mucosal vaccines , 2014, Human vaccines & immunotherapeutics.

[49]  S. Strome,et al.  The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. , 2014, Oral oncology.

[50]  M. Dolled-Filhart,et al.  A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. , 2014 .

[51]  N. Segal,et al.  Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. , 2014 .

[52]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[53]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[54]  R. Ferris,et al.  Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients , 2013, British Journal of Cancer.

[55]  A. Skálová,et al.  Mammary Analogue Secretory Carcinoma of Salivary Gland Origin: An Update and Expanded Morphologic and Immunohistochemical Spectrum of Recently Described Entity , 2013, Head and Neck Pathology.

[56]  T. Nyberg,et al.  CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.

[57]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[58]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[59]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[60]  W. Thorstad,et al.  B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma , 2013, Head and Neck Pathology.

[61]  Y. Zeng,et al.  Tumor Microenvironment Macrophage Inhibitory Factor Directs the Accumulation of Interleukin-17-producing Tumor-infiltrating Lymphocytes and Predicts Favorable Survival in Nasopharyngeal Carcinoma Patients* , 2012, The Journal of Biological Chemistry.

[62]  L. Zitvogel,et al.  Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer , 2012, Oncoimmunology.

[63]  Yun Feng,et al.  Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. , 2012, Immunobiology.

[64]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[65]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[66]  Y. Cho,et al.  Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. , 2011, Oral oncology.

[67]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[68]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[69]  I. Su,et al.  Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma , 2010, Modern Pathology.

[70]  E. Tartour,et al.  Better understanding tumor–host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies , 2010, Head & neck.

[71]  A. Fauci,et al.  The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.

[72]  E. Tartour,et al.  The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. , 2008, Cancer research.

[73]  P. Albert,et al.  Nuclear Factor-κB–Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma , 2007, Clinical Cancer Research.

[74]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[75]  R. Ferris,et al.  Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer , 2006, Clinical Cancer Research.

[76]  R. Ferris,et al.  Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[77]  A. Weaver,et al.  Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  M. Burnet.  Cancer—A Biological Approach , 1957, British medical journal.